Winston-Salem, N.C. – August 4, 2024 – FetTech, LLC, a manufacturer of materials for regenerative medicine therapies, is bringing their expertise to the NSF-Piedmont Triad RegenMed Engine (PTRME) ecosystem. This collaboration aims to enhance the development and clinical translation of innovative therapies using FetTech’s Multi-Tissue Platform (MTP) technology. Their line-up of technologies include VyraMed, XCelliStem Wound Powder, and ReyaGel. The NSF-PTRME Test Bed is an initiative from the RegenMed Development Organization (ReMDO), part of the Piedmont Triad RegenMed Engine of the National Science Foundation (NSF) Innovation Engines program.
FetTech’s MTP technology revolutionizes healing by utilizing naturally derived tissues solutions, combining multiple tissue sources, to provide essential biomolecules that enhance the body’s regenerative capabilities, promoting faster and more effective healing. For the Test Bed, FetTech will be contributing ReyaGel clinical biomaterial, an FDA-approved solution composed of collagen, elastin and growth factors to assist in bioprinting and manufacturing lab-grown tissue and organs.
“For the Test Bed, a partner such as FetTech is vital in establishing new relationships working towards innovative commercial technologies and products,” describes Joshua Hunsberger, CTO for ReMDO.
The NSF-PTRME Test Bed offers a collaborative environment for pioneering companies in the regenerative medicine space, providing access to state-of-the-art facilities and expertise. FetTech’s participation provides a continued commitment to innovation and excellence in developing cutting-edge medical solutions by onboarding partners in the industry, academia, and science.
About ReMDO: The RegenMed Development Organization (ReMDO) is a 501(c)3 non-profit with a mission to help deliver on the promise of regenerative medicine by advancing research to de-risk technologies, promoting progress of biomanufacturing scale-up and automation to make technologies more affordable, and speeding up the translation to clinical practice. For more information, visit http://remdo.org.
For inquiries regarding the RegeneratOR Test Bed and partnership opportunities, please contact [email protected].
About the NSF-PTRME: The NSF-PTRME is an initiative to build a regional innovation ecosystem to accelerate the translation of regenerative medicine use-inspired research to commercialization, thus stimulating economic growth, workforce development, and job creation. The PTRME partnership consists of members of the RegenMed Hub, ReMDO, members of the Regenerative Manufacturing Innovation Consortium (RegMIC), and includes more than 80 regional stakeholders in academia, industry, government, and not-for profit entities. The PTRME core team consists of organizations in the industry with Axiom Space and ReMDO paired with academic institutions such as North Carolina Agricultural and Technical State University (NC A&T), Winston Salem State University (WSSU), and Forsyth Technical Community College, supported by multiple businesses, governmental entities, and not-for-profit agencies.
Media Contact: Stefanie Walling, [email protected]
About FetTech, LLC: FetTech is a regenerative medicine company making breakthroughs in regenerative technologies & virology. We developed our revolutionary Multi-Tissue Platform (MTP) technology to bring the power of regenerative medicine to the biggest gaps and unsolved challenges in healthcare today. FDA-cleared MTP products have already supported wound healing in thousands of patients. During our development of these first products, we discovered that MTP in both powder and gel/liquid forms has innate broad-spectrum antiviral activity against enveloped viruses. MTP-based therapies for either regenerative or antiviral applications (or both) can be designed for use alone or in conjunction with other therapies. The future possibilities with MTP are endless, including inhalable, injectable, intravenous, and ophthalmic routes of administration.
Media Contact: Juliet Hahn, [email protected]